Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Geriatric Use)

In this article, we will discuss Olaparib (Geriatric Use). So, let’s get started.

Geriatric Use
In clinical studies of Olaparib enrolling 687 patients with advanced solid tumors who received Olaparib tablets 300 mg twice daily as monotherapy, 146 (21%) patients were aged ≥65 years, and this included 29 (4%) patients who were aged ≥75 years. No patients were aged ≥85 years. No overall differences in the safety or effectiveness of Olaparib were observed between younger and older patients.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.